While caution is being exercised everywhere about the dangers of the drug montelukast, its sale in India is unregulated, ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Report on how AI is driving market transformation- The global diisocyanates and polyisocyanates market size is estim ...

The standard of nicotine (99.7%) was obtained from Merck Chemicals. Glycerol (99.5% ... is a non-toxic chemical widely used as humectants in food products and as additives in asthma inhalers and ...

Three years ago, the cigarette giant acquired Vectura, a British pharmaceutical firm that makes asthma inhalers, raising ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to the first study to show such a benefit in these patients. After five ...

When a pharmaceutical company such as Merck has an extremely successful product such as Keytruda, it can be both a blessing and a curse. Keytruda is a significant source of revenue growth for the ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.